Mammalian Genomics

J. Craig Venter, PhD and his research teams have been at the forefront of mammalian genomics for more than two decades. Their pioneering work began in 1991 while at the National Institutes of Health by developing a technique, expressed sequence tags or ESTs, to rapidly identify human genes. Dr. Venter and some from the team later went on to publish the first draft sequence of the human genome in 2001 at a company he co-founded called Celera Genomics, and then the first complete diploid human genome at JCVI in 2007. Complementing human DNA advancements, JCVI President, Karen Nelson, PhD, and a team of collaborators led the landmark first study on the human gut microbiome, cataloging life found in the human gut. These seminal studies have helped accelerate us towards the goal of truly individualized genomic medicine. Building on these advancements, JCVI is expanding its portfolio to include flu vaccine development, novel autoimmune disease research in areas such as multiple sclerosis, and metabolic diseases, including type 1 and 2 diabetes.

Mammalian Genomics

J. Craig Venter, PhD and his research teams have been at the forefront of mammalian genomics for more than two decades. Their pioneering work began in 1991 while at the National Institutes of Health by developing a technique, expressed sequence tags or ESTs, to rapidly identify human genes. Dr. Venter and some from the team later went on to publish the first draft sequence of the human genome in 2001 at a company he co-founded called Celera Genomics, and then the first complete diploid human genome at JCVI in 2007. Complementing human DNA advancements, JCVI President, Karen Nelson, PhD, and a team of collaborators led the landmark first study on the human gut microbiome, cataloging life found in the human gut. These seminal studies have helped accelerate us towards the goal of truly individualized genomic medicine. Building on these advancements, JCVI is expanding its portfolio to include flu vaccine development, novel autoimmune disease research in areas such as multiple sclerosis, and metabolic diseases, including type 1 and 2 diabetes.